View profile

FarmaKology Newsletter - Issue #4

Would you like to submit an article, some interesting news, or get your startup featured? Send whatev


April 2 · Issue #4 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to “”, and happy to have you featured on our newsletter!

Today's Startup
PillPack leverages service and technology to simplify the management of complex medication regimens for the 32 million people taking more than 5 medications a month. It uses design to create an unparalleled patient experience that is both satisfying and effective.
A change in protocol for the treatment of severe malaria has been announced by the US Centers for Disease Control and Prevention (CDC). The agency announced today that as of April 1, 2019, artesunate will become the first-line treatment for severe malaria in the United States.
Allena Pharmaceuticals has signed an agreement with the Duke Clinical Research Institute (DCRI) for the URIROX-2 Phase III clinical trial evaluating the safety and efficacy of reloxaliase in the treatment of patients with enteric hyperoxaluria.
Dutch biotechnology company, Micreos has raised €30 million for endolysin technology to replace antibiotics.
In a civil suit filed Thursday, New York state Attorney General Letitia James accused eight members of the Sackler family, owners of Purdue Pharma, of triggering and then profiting off the U.S. opioid epidemic through their marketing of Oxycontin, a highly addictive painkiller.
The Bright Side Thursday March 28 2019 Bright Side podcast
Job Opportunities
The Future of Pharma with Jeremy Levin
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue